Fidelis Capital Partners LLC Buys 5,923 Shares of Cardinal Health, Inc. $CAH

Fidelis Capital Partners LLC lifted its stake in Cardinal Health, Inc. (NYSE:CAH) by 296.0% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 7,924 shares of the company’s stock after buying an additional 5,923 shares during the quarter. Fidelis Capital Partners LLC’s holdings in Cardinal Health were worth $1,244,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently made changes to their positions in the stock. SJS Investment Consulting Inc. raised its stake in Cardinal Health by 1,363.6% during the 3rd quarter. SJS Investment Consulting Inc. now owns 161 shares of the company’s stock worth $25,000 after acquiring an additional 150 shares during the period. Atlantic Edge Private Wealth Management LLC increased its stake in shares of Cardinal Health by 75.0% in the second quarter. Atlantic Edge Private Wealth Management LLC now owns 175 shares of the company’s stock worth $29,000 after purchasing an additional 75 shares in the last quarter. Vermillion & White Wealth Management Group LLC increased its stake in shares of Cardinal Health by 55.0% in the second quarter. Vermillion & White Wealth Management Group LLC now owns 200 shares of the company’s stock worth $34,000 after purchasing an additional 71 shares in the last quarter. American Capital Advisory LLC raised its position in shares of Cardinal Health by 5,200.0% during the 3rd quarter. American Capital Advisory LLC now owns 212 shares of the company’s stock valued at $33,000 after purchasing an additional 208 shares during the period. Finally, NewSquare Capital LLC lifted its stake in shares of Cardinal Health by 100.0% during the 2nd quarter. NewSquare Capital LLC now owns 214 shares of the company’s stock valued at $36,000 after buying an additional 107 shares in the last quarter. 87.17% of the stock is owned by hedge funds and other institutional investors.

Cardinal Health News Roundup

Here are the key news stories impacting Cardinal Health this week:

• Positive Sentiment: Cardinal hit an all-time high, reinforcing upside momentum and drawing more attention from momentum and trend-following buyers. Cardinal Health stock hits all-time high at $215.54
• Positive Sentiment: Morgan Stanley upgraded competitor Cencora, calling a “golden era” for drug distributors — a sector-level endorsement that likely lifts sentiment for Cardinal as a leading distributor. Cencora upgraded as Morgan Stanley cites a “golden era” for drug distributors
• Positive Sentiment: Multiple brokers and analysts are highlighting CAH as a top pick for Q4/early 2026, citing solid earnings trends and cooled inflation — this increases the likelihood of continued analyst revisions and inflows. 5 Broker-Loved Stocks to Watch Amid Steady Start to Q4 Earnings Season
• Positive Sentiment: Zacks expects CAH to report growing earnings next week and notes the company has the characteristics of a likely earnings beat — a near-term catalyst that can push the stock higher if results confirm expectations. Cardinal Health (CAH) Earnings Expected to Grow: What to Know Ahead of Next Week’s Release
• Positive Sentiment: High-profile bullish commentary (e.g., Jim Cramer saying he can see CAH reaching $300) can attract retail flows and increase trading momentum. Jim Cramer on Cardinal Health: “I Can See That Stock Going to $300”
• Positive Sentiment: IBD highlights raised 2026 guidance and strong momentum, reinforcing the narrative that growth and execution are improving — supports higher valuations. IBD Stock Of The Day: Why Cardinal Health’s Momentum Is ‘Special’ — And Not Over Yet
• Positive Sentiment: Short interest fell ~15.9% in January, lowering potential downside pressure from short-covering dynamics and removing a near-term bearish crowd — fewer shorts can mean steadier rallies. (data summary)
• Neutral Sentiment: Zacks published a valuation-focused piece asking whether CAH is undervalued — useful for longer-term investors but less of an immediate price catalyst. Is Cardinal Health (CAH) Stock Undervalued Right Now?
• Neutral Sentiment: Routine earnings calendar note: Cardinal is expected to announce quarterly results Thursday — the report itself is the key near-term event that could change the stock’s direction. Cardinal Health (CAH) Expected to Announce Quarterly Earnings on Thursday

Analysts Set New Price Targets

CAH has been the subject of a number of analyst reports. Morgan Stanley increased their price target on Cardinal Health from $224.00 to $245.00 and gave the stock an “overweight” rating in a research note on Thursday. Wells Fargo & Company increased their target price on Cardinal Health from $221.00 to $237.00 and gave the stock an “overweight” rating in a research report on Thursday, January 15th. Wall Street Zen raised Cardinal Health from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 8th. Weiss Ratings restated a “buy (b)” rating on shares of Cardinal Health in a research note on Wednesday, January 21st. Finally, UBS Group lifted their price objective on shares of Cardinal Health from $185.00 to $220.00 and gave the company a “buy” rating in a research report on Friday, October 31st. Fourteen investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $224.73.

Cardinal Health Stock Up 0.3%

Cardinal Health stock opened at $211.02 on Friday. The company’s 50-day moving average price is $206.13 and its 200-day moving average price is $177.53. The company has a market cap of $50.14 billion, a PE ratio of 31.83, a price-to-earnings-growth ratio of 1.43 and a beta of 0.65. Cardinal Health, Inc. has a twelve month low of $120.72 and a twelve month high of $216.51.

Cardinal Health (NYSE:CAH) last released its quarterly earnings results on Thursday, October 30th. The company reported $2.55 EPS for the quarter, topping the consensus estimate of $2.22 by $0.33. Cardinal Health had a negative return on equity of 84.37% and a net margin of 0.68%.The company had revenue of $64.01 billion during the quarter, compared to analyst estimates of $59.41 billion. During the same quarter last year, the business posted $1.88 earnings per share. The firm’s revenue was up 22.4% on a year-over-year basis. As a group, sell-side analysts expect that Cardinal Health, Inc. will post 7.95 earnings per share for the current fiscal year.

Cardinal Health Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, January 15th. Investors of record on Friday, January 2nd were given a $0.5107 dividend. The ex-dividend date was Friday, January 2nd. This represents a $2.04 dividend on an annualized basis and a yield of 1.0%. Cardinal Health’s dividend payout ratio (DPR) is currently 30.77%.

Cardinal Health Profile

Cardinal Health is a multinational healthcare services and products company headquartered in Dublin, Ohio. Tracing its roots to the early 1970s, the company has grown into a major provider of supply chain and distribution services for the healthcare sector. Cardinal Health operates across a range of service lines that support hospitals, health systems, pharmacies, physician offices and clinical laboratories.

The company’s core activities include the wholesale distribution of branded and generic pharmaceuticals, the supply and distribution of medical-surgical products, and the provision of logistics and inventory management solutions.